Amgen’s greenfield facility near Columbus, Ohio to assemble and package vials and syringes is expected to be operational by 2024.
Amgen announced in a June 29, 2021 press release that it plans to expand its US-based manufacturing footprint by building a new, final product advanced assembly and packaging plant near Columbus, Ohio. The company plans to invest $365 million in the new greenfield facility, which will assemble and package vials and syringes.
"We are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world,” said Esteban Santos, executive vice-president of Operations at Amgen. “We are pleased to build this final product assembly and packaging plant in the Columbus region which will support the anticipated growth in demand for Amgen medicines, create hundreds of new jobs, and feature advanced digital automation."
Plant construction is expected to begin in the fall of 2021 and is expected to be operational by 2024. The new facility will be designed to maximize energy efficiency and waste reduction, as part of Amgen’s plan to make its operations carbon neutral by 2027.
At full capacity, Amgen plans to have hired up to 400 full-time staff, including technicians and engineers, along with quality assurance, quality control, administrative, and management positions. According to the press release, the new facility will play an important role in achieving Amgen’s commitment to OneTen, a coalition of companies that aims collectively to hire one million Black Americans into well-paying jobs over the next ten years, with a specific focus on those without a four-year college degree.
Source: Amgen
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.